vs
安捷伦科技（A）与FMC CORP（FMC）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是FMC CORP的1.7倍（$1.8B vs $1.1B），安捷伦科技净利率更高（17.0% vs -158.8%，领先175.8%），安捷伦科技同比增速更快（7.0% vs -11.5%），FMC CORP自由现金流更多（$631.1M vs $175.0M），过去两年FMC CORP的营收复合增速更高（8.6% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
FMC公司是总部位于美国宾夕法尼亚州费城的化工制造企业，1883年创立之初以生产杀虫剂为主，后续逐步拓展业务至其他领域。二战期间曾为美国陆军部设计生产两栖履带登陆车，目前在全球拥有7000名员工，业务布局广泛。
A vs FMC — 直观对比
营收规模更大
A
是对方的1.7倍
$1.1B
营收增速更快
A
高出18.5%
-11.5%
净利率更高
A
高出175.8%
-158.8%
自由现金流更多
FMC
多$456.1M
$175.0M
两年增速更快
FMC
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.1B |
| 净利润 | $305.0M | $-1.7B |
| 毛利率 | 52.6% | 39.8% |
| 营业利润率 | 19.6% | -130.8% |
| 净利率 | 17.0% | -158.8% |
| 营收同比 | 7.0% | -11.5% |
| 净利润同比 | -4.1% | -10457.1% |
| 每股收益（稀释后） | $1.07 | $-13.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFMC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.1B | ||
| Q3 25 | $1.7B | $542.2M | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.7B | $791.4M | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.6B | $1.0B |
净利润AFMC
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-1.7B | ||
| Q3 25 | $336.0M | $-569.3M | ||
| Q2 25 | $215.0M | $66.7M | ||
| Q1 25 | $318.0M | $-15.5M | ||
| Q4 24 | $351.0M | $-16.3M | ||
| Q3 24 | $282.0M | $65.0M | ||
| Q2 24 | $308.0M | $295.1M |
毛利率AFMC
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 39.8% | ||
| Q3 25 | 51.1% | 23.8% | ||
| Q2 25 | 51.9% | 38.7% | ||
| Q1 25 | 53.5% | 40.0% | ||
| Q4 24 | 53.9% | 42.9% | ||
| Q3 24 | 54.2% | 36.3% | ||
| Q2 24 | 54.4% | 38.3% |
营业利润率AFMC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -130.8% | ||
| Q3 25 | 20.7% | -73.1% | ||
| Q2 25 | 18.0% | 12.0% | ||
| Q1 25 | 22.4% | 7.4% | ||
| Q4 24 | 24.0% | 19.2% | ||
| Q3 24 | 21.1% | 12.7% | ||
| Q2 24 | 23.1% | 6.0% |
净利率AFMC
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -158.8% | ||
| Q3 25 | 19.3% | -105.0% | ||
| Q2 25 | 12.9% | 6.3% | ||
| Q1 25 | 18.9% | -2.0% | ||
| Q4 24 | 20.6% | -1.3% | ||
| Q3 24 | 17.9% | 6.1% | ||
| Q2 24 | 19.6% | 28.4% |
每股收益（稀释后）AFMC
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-13.77 | ||
| Q3 25 | $1.18 | $-4.52 | ||
| Q2 25 | $0.75 | $0.53 | ||
| Q1 25 | $1.11 | $-0.12 | ||
| Q4 24 | $1.23 | $-0.13 | ||
| Q3 24 | $0.97 | $0.52 | ||
| Q2 24 | $1.05 | $2.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $584.5M |
| 总债务越低越好 | $3.0B | $3.4B |
| 股东权益账面价值 | $6.9B | $2.1B |
| 总资产 | $12.8B | $9.7B |
| 负债/权益比越低杠杆越低 | 0.44× | 1.62× |
8季度趋势，按日历期对齐
现金及短期投资AFMC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $584.5M | ||
| Q3 25 | $1.5B | $497.7M | ||
| Q2 25 | $1.5B | $438.2M | ||
| Q1 25 | $1.5B | $315.3M | ||
| Q4 24 | $1.3B | $357.3M | ||
| Q3 24 | $1.8B | $416.7M | ||
| Q2 24 | $1.7B | $471.5M |
总债务AFMC
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $3.4B | ||
| Q3 25 | $3.4B | $3.4B | ||
| Q2 25 | $3.3B | $3.4B | ||
| Q1 25 | $3.3B | $3.1B | ||
| Q4 24 | $3.3B | $3.1B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.1B | $3.1B |
股东权益AFMC
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $2.1B | ||
| Q3 25 | $6.4B | $3.8B | ||
| Q2 25 | $6.1B | $4.4B | ||
| Q1 25 | $6.0B | $4.4B | ||
| Q4 24 | $5.9B | $4.5B | ||
| Q3 24 | $5.9B | $4.6B | ||
| Q2 24 | $6.2B | $4.6B |
总资产AFMC
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $9.7B | ||
| Q3 25 | $12.2B | $12.1B | ||
| Q2 25 | $12.2B | $12.3B | ||
| Q1 25 | $11.9B | $11.8B | ||
| Q4 24 | $11.8B | $11.7B | ||
| Q3 24 | $11.0B | $12.2B | ||
| Q2 24 | $10.9B | $12.1B |
负债/权益比AFMC
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.62× | ||
| Q3 25 | 0.53× | 0.89× | ||
| Q2 25 | 0.55× | 0.76× | ||
| Q1 25 | 0.56× | 0.71× | ||
| Q4 24 | 0.57× | 0.69× | ||
| Q3 24 | 0.36× | 0.68× | ||
| Q2 24 | 0.34× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $657.1M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $631.1M |
| 自由现金流率自由现金流/营收 | 9.7% | 58.3% |
| 资本支出强度资本支出/营收 | 5.2% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $-102.5M |
8季度趋势，按日历期对齐
经营现金流AFMC
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $657.1M | ||
| Q3 25 | $362.0M | $-184.2M | ||
| Q2 25 | $221.0M | $65.9M | ||
| Q1 25 | $431.0M | $-545.0M | ||
| Q4 24 | $481.0M | $427.9M | ||
| Q3 24 | $452.0M | $159.5M | ||
| Q2 24 | $333.0M | $292.2M |
自由现金流AFMC
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $631.1M | ||
| Q3 25 | $259.0M | $-207.9M | ||
| Q2 25 | $107.0M | $50.9M | ||
| Q1 25 | $334.0M | $-576.6M | ||
| Q4 24 | $388.0M | $406.3M | ||
| Q3 24 | $360.0M | $143.8M | ||
| Q2 24 | $230.0M | $282.3M |
自由现金流率AFMC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 58.3% | ||
| Q3 25 | 14.9% | -38.3% | ||
| Q2 25 | 6.4% | 4.8% | ||
| Q1 25 | 19.9% | -72.9% | ||
| Q4 24 | 22.8% | 33.2% | ||
| Q3 24 | 22.8% | 13.5% | ||
| Q2 24 | 14.6% | 27.2% |
资本支出强度AFMC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 2.4% | ||
| Q3 25 | 5.9% | 4.4% | ||
| Q2 25 | 6.8% | 1.4% | ||
| Q1 25 | 5.8% | 4.0% | ||
| Q4 24 | 5.5% | 1.8% | ||
| Q3 24 | 5.8% | 1.5% | ||
| Q2 24 | 6.5% | 1.0% |
现金转化率AFMC
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | 0.99× | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | 2.45× | ||
| Q2 24 | 1.08× | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
FMC
| Insecticides | $440.3M | 41% |
| Herbicides | $378.8M | 35% |
| Fungicides | $140.4M | 13% |
| Plant Health | $65.6M | 6% |
| Other | $45.0M | 4% |
